Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCRbeta-HOXA rearrangement: a study of the Groupe Francophone de Cytogénétique Hématologique. Cauwelier, B., Cavé, H., Gervais, C, Lessard, M., Barin, C, Perot, C, den Akker, J V., Mugneret, F, Charrin, C, Pagès, M P, Grégoire, M J, Jonveaux, P, Lafage-Pochitaloff, M., Mozzicconacci, M J, Terré, C, Luquet, I, Cornillet-Lefebvre, P, Laurence, B, Plessis, G, Lefebvre, C, Leroux, D, Antoine-Poirel, H, Graux, C., Mauvieux, L., Heimann, P, Chalas, C, Clappier, E, Verhasselt, B., Benoit, Y., Moerloose, B D, Poppe, B., Roy, N. V., Keersmaecker, K D, Cools, J., Sigaux, F, Soulier, J, Hagemeijer, A., Paepe, A. D., Dastugue, N., Berger, R, & Speleman, F. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 21(1):121--8, January, 2007.
Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCRbeta-HOXA rearrangement: a study of the Groupe Francophone de Cytogénétique Hématologique. [link]Paper  abstract   bibtex   
Recently, we and others described a new chromosomal rearrangement, that is, inv(7)(p15q34) and t(7;7)(p15;q34) involving the T-cell receptor beta (TCRbeta) (7q34) and the HOXA gene locus (7p15) in 5% of T-cell acute lymphoblastic leukemia (T-ALL) patients leading to transcriptional activation of especially HOXA10. To further address the clinical, immunophenotypical and molecular genetic findings of this chromosomal aberration, we studied 330 additional T-ALLs. This revealed TCRbeta-HOXA rearrangements in five additional patients, which brings the total to 14 cases in 424 patients (3.3%). Real-time quantitative PCR analysis for HOXA10 gene expression was performed in 170 T-ALL patients and detected HOXA10 overexpression in 25.2% of cases including all the cases with a TCRbeta-HOXA rearrangement (8.2%). In contrast, expression of the short HOXA10 transcript, HOXA10b, was almost exclusively found in the TCRbeta-HOXA rearranged cases, suggesting a specific role for the HOXA10b short transcript in TCRbeta-HOXA-mediated oncogenesis. Other molecular and/or cytogenetic aberrations frequently found in subtypes of T-ALL (SIL-TAL1, CALM-AF10, HOX11, HOX11L2) were not detected in the TCRbeta-HOXA rearranged cases except for deletion 9p21 and NOTCH1 activating mutations, which were present in 64 and 67%, respectively. In conclusion, this study defines TCRbeta-HOXA rearranged T-ALLs as a distinct cytogenetic subgroup by clinical, immunophenotypical and molecular genetic characteristics.
@article{ Cauwelier2007,
  author    = {Barbara Cauwelier and Hélène Cavé and C Gervais and Michel Lessard and C Barin and C Perot and J Van den Akker and F Mugneret and C Charrin and M P Pagès and M J Grégoire and P Jonveaux and Marina Lafage-Pochitaloff and M J Mozzicconacci and C Terré and I Luquet and P Cornillet-Lefebvre and B Laurence and G Plessis and C Lefebvre and D Leroux and H Antoine-Poirel and Carlos Graux and Laurent Mauvieux and P Heimann and C Chalas and E Clappier and Bruno Verhasselt and Yves Benoit and B D Moerloose and Bruce Poppe and Nadine Van Roy and K D Keersmaecker and Jan Cools and F Sigaux and J Soulier and Anne Hagemeijer and Anne De Paepe and Nicole Dastugue and R Berger and Frank Speleman},
  title     = {Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCRbeta-HOXA rearrangement: a study of the Groupe Francophone de Cytogénétique Hématologique.},
  journal   = {Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K}, 
  abstract   = {Recently, we and others described a new chromosomal rearrangement, that is, inv(7)(p15q34) and t(7;7)(p15;q34) involving the T-cell receptor beta (TCRbeta) (7q34) and the HOXA gene locus (7p15) in 5\% of T-cell acute lymphoblastic leukemia (T-ALL) patients leading to transcriptional activation of especially HOXA10. To further address the clinical, immunophenotypical and molecular genetic findings of this chromosomal aberration, we studied 330 additional T-ALLs. This revealed TCRbeta-HOXA rearrangements in five additional patients, which brings the total to 14 cases in 424 patients (3.3\%). Real-time quantitative PCR analysis for HOXA10 gene expression was performed in 170 T-ALL patients and detected HOXA10 overexpression in 25.2\% of cases including all the cases with a TCRbeta-HOXA rearrangement (8.2\%). In contrast, expression of the short HOXA10 transcript, HOXA10b, was almost exclusively found in the TCRbeta-HOXA rearranged cases, suggesting a specific role for the HOXA10b short transcript in TCRbeta-HOXA-mediated oncogenesis. Other molecular and/or cytogenetic aberrations frequently found in subtypes of T-ALL (SIL-TAL1, CALM-AF10, HOX11, HOX11L2) were not detected in the TCRbeta-HOXA rearranged cases except for deletion 9p21 and NOTCH1 activating mutations, which were present in 64 and 67\%, respectively. In conclusion, this study defines TCRbeta-HOXA rearranged T-ALLs as a distinct cytogenetic subgroup by clinical, immunophenotypical and molecular genetic characteristics.},
  issn   = {0887-6924},
  month   = {January},
  pages   = {121--8},
  volume   = {21},
  number   = {1},
  url   = {http://www.ncbi.nlm.nih.gov/pubmed/17039236} ,
  year   = {2007}
}

Downloads: 0